Resorcinol
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Resorcinol: From Acne and Dermatitis to Acne Keloid
One-Sentence Summary
Resorcinol is a topical agent originally used for acne and related inflammatory skin conditions (dermatitis, acneiform dermatitis). The TxGNN model predicts it may be useful for acne keloid (acne keloidalis), but no clinical trials and no publications were found in the data compiled for this report, so the prediction rests on the model score and plausible mechanism alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne, dermatitis, acneiform dermatitis (from the TxGNN knowledge graph; no approved indication text is recorded for the Australian entry) |
| Predicted New Indication | Acne keloid |
| TxGNN Prediction Score | 0.9983 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Based on known information, resorcinol is a topical keratolytic and antiseptic agent. Its use in acne and related inflammatory skin conditions is established, and mechanistically it may be applicable to acne keloidalis.
Acne keloidalis (folliculitis keloidalis) is a chronic inflammatory condition of the hair follicles, typically on the back of the neck and scalp. It shares follicular inflammation with acne, so a keratolytic and antiseptic action is a plausible fit.
This link is a hypothesis only. No trials or literature were available to test it, and the case rests on the approved acne use and the high model score.
Other predictions for this drug (for example amyopathic dermatomyositis, rheumatoid vasculitis, ankylosing spondylitis and polyarticular juvenile rheumatoid arthritis) have no plausible mechanism and no evidence. They appear to be computational artefacts and are not recommended for further evaluation. Use in neonates and children also raises systemic absorption concerns, including methaemoglobinaemia and thyroid effects.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Licence 433T (listed in the data compiled for this report; confirm the ARTG number against the register) | Not recorded | Not recorded | Not recorded |
Safety Considerations
No label-based warnings or contraindications were available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
No drug interaction records were found.
The TxGNN model (deep learning) links resorcinol to the following conditions as contraindications. These come from the model and not from label text, and may reflect similarities the model learned between related diseases, not biological evidence, so they must be verified against the PI:
- Blood and metabolic: G6PD deficiency, methaemoglobinaemia (including reductase deficiency), sulfhaemoglobinaemia, diabetes mellitus, diabetic ketoacidosis, glycogen storage disease, cystinuria, galactosaemia, pyruvate dehydrogenase E3 deficiency
- Cardiorespiratory and vascular: sudden cardiac arrest, heart conduction disease, respiratory failure, peripheral vascular disease, intermittent claudication, peripheral arterial disease
- Kidney and neurological: kidney disease, pyoureter, epilepsy
- Skin: dermatitis, seborrhoeic dermatitis, folliculitis, exanthem, common wart, anogenital human papillomavirus infection
Folliculitis and dermatitis appear on this list. This is directly relevant to a follicular inflammatory condition such as acne keloidalis and needs clarification.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support for acne keloid is a high model score (L4) and a plausible keratolytic and antiseptic rationale. There are no trials or publications, and the knowledge graph lists folliculitis and dermatitis as contraindications, which conflicts with the proposed use.
To proceed, the following is needed:
- The TGA-approved Product Information (PI) for warnings, contraindications and approved indications, and confirmation of the ARTG entry details (product name, dosage form, indication)
- Mechanism of action data (for example from DrugBank)
- A literature search for resorcinol in acne keloidalis and folliculitis keloidalis
- Clarification of the knowledge graph contraindications for folliculitis and dermatitis
- Assessment of systemic absorption risk on inflamed or broken skin, and a safety plan for children and neonates
- A pilot or case-series study if the above review is favourable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.